Microbiota Lab, Department of Pharmacognosy and Molecular Basis of Phytotherapy, Medical University of Warsaw, Warsaw, Poland.
Department of Psychiatry, Collegium Medicum, Jagiellonian University, Cracow, Poland.
Phytomedicine. 2023 Mar;111:154642. doi: 10.1016/j.phymed.2023.154642. Epub 2023 Jan 4.
Clinical research in natural product-based psychopharmacology has revealed a variety of promising herbal medicines that may provide benefit in the treatment of mild mood disorders, however failed to unambiguously indicate pharmacologically active constituents. The emerging role of the microbiota-gut-brain axis opens new possibilities in the search for effective methods of treatment and prevention of mood disorders.
Considering the clinically proven effectiveness juxtaposed with inconsistencies regarding the indication of active principles for many medicinal plants applied in the treatment of anxiety and depression, the aim of the review is to look at their therapeutic properties from the perspective of the microbiota-gut-brain axis.
A literature-based survey was performed using Scopus, Pubmed, and Google Scholar databases. The current state of knowledge regarding Hypericum perforatum, Valeriana officinalis, Piper methysticum, Passiflora incarnata, Humulus lupulus, Melissa officinalis, Lavandula officinalis, and Rhodiola rosea in terms of their antimicrobial activity, bioavailability, clinical effectiveness in depression/anxiety and gut microbiota - natural products interaction was summarized and analyzed.
Recent studies have provided direct and indirect evidence that herbal extracts and isolated compounds are potent modulators of gut microbiota structure. Additionally, some of the formed postbiotic metabolites exert positive effects and ameliorate depression-related behaviors in animal models of mood disorders. The review underlines the gap in research on natural products - gut microbiota interaction in the context of mood disorders.
Modification of microbiota-gut-brain axis by natural products is a plausible explanation of their therapeutic properties. Future studies evaluating the effectiveness of herbal medicine and isolated compounds in treating mild mood disorders should consider the bidirectional interplay between phytoconstituents and the gut microbiota community.
基于天然产物的精神药理学的临床研究揭示了多种有前途的草药，它们可能在治疗轻度情绪障碍方面提供益处，但未能明确指出具有药理活性的成分。微生物群-肠道-大脑轴的新作用为寻找治疗和预防情绪障碍的有效方法开辟了新的可能性。
鉴于许多用于治疗焦虑和抑郁的药用植物的临床疗效已得到证实，但在表明其有效成分的指示方面存在不一致，因此，本综述的目的是从微生物群-肠道-大脑轴的角度来看待它们的治疗特性。
使用 Scopus、Pubmed 和 Google Scholar 数据库进行文献综述。总结和分析贯叶连翘、缬草、卡瓦胡椒、西番莲、啤酒花、柠檬香脂、薰衣草和玫瑰茄在抗微生物活性、生物利用度、抗抑郁/焦虑的临床疗效以及肠道微生物群-天然产物相互作用方面的最新知识状况。
最近的研究提供了直接和间接的证据，表明草药提取物和分离化合物是肠道微生物群结构的有效调节剂。此外，一些形成的后生元代谢物对改善情绪障碍动物模型的抑郁相关行为具有积极作用。该综述强调了在情绪障碍背景下，天然产物-肠道微生物群相互作用研究中的空白。
天然产物对微生物群-肠道-大脑轴的修饰是其治疗特性的合理解释。未来评估草药和分离化合物治疗轻度情绪障碍的有效性的研究应考虑植物成分与肠道微生物群落之间的双向相互作用。
